Showing results (101-110 of 148) with videos related to
Sort By:
Pageof 15
Plos One|December 29, 2016
HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in ItalyDavide Croce, Adriano Lazzarin, Giuliano Rizzardini, et al.Journal of Hypertension|December 23, 2016
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension StudyGiuseppe Vittorio De Socio, Elena Ricci, Paolo Maggi, et al.American Journal of Hypertension|October 1, 2013
Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY studyGiuseppe Vittorio De Socio, Elena Ricci, Paolo Maggi, et al.Infection and Drug Resistance|August 9, 2020
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World CohortPaolo Bonfanti, Andrea De Vito, Elena Ricci, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 19, 2012
The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective studyPaolo Bonfanti, Giuseppe Vittorio De Socio, Elena Ricci, et al.BMC Public Health|May 22, 2020
Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional studyGiuseppe Vittorio De Socio, Marta Pasqualini, Elena Ricci, et al.Journal of Women & Aging|January 26, 2018
Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experiencePaola Vitiello, Lucia Taramasso, Elena Ricci, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 19, 2007
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA ProjectGiordano Madeddu, Paolo Bonfanti, Giuseppe V De Socio, et al.The Journal of Infection|April 26, 2008
Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE studyGiuseppe Vittorio L De Socio, Giustino Parruti, Tiziana Quirino, et al.BMC Infectious Diseases|August 2, 2018
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)Lucia Taramasso, Paola Tatarelli, Elena Ricci, et al.Pageof 15